Introduction
MHC class II gene expression is tightly regulated in a cell lineage speci®c manner with two modes of activation, constitutive or inducible. Constitutive expression of MHC class II genes is restricted to specialized antigen presenting cells, such as B lymphocytes and dendritic cells. MHC class II expression can also be induced in many other cell types by IFN-g and other stimuli (Collins et al., 1984; Basta et al., 1987; Glimcher and Kara, 1992; Ting and Baldwin, 1993; Mach et al., 1996; Rohn et al., 1996) . Mice with a targeted disruption of the IFN-g gene are incapable of expressing MHC class II as well as class I genes in response to many pathogenic stimuli (Goes et al., 1995) .
Both constitutive and IFN-g inducible expression of the MHC class II genes are directly controlled by a transcriptional coactivator, class II transactivator (CIITA) (Steimle et al., 1993 (Steimle et al., , 1994 Chang et al., 1994 Chang et al., , 1996 Chin et al., 1994) . CIITA is believed to be recruited to the MHC class II promoter by interactions with sequence-speci®c transcription factors bound to the regulatory elements of the MHC class II promoters (e.g., RFX5) (Riley et al., 1995; Scholl et al., 1997; Fontes et al., 1996 Fontes et al., , 1999 Kretsovali et al., 1998; Moreno et al., 1999; Zhu et al., 2000) . The aminoterminal activation domain of CIITA is thought to be responsible for activation of the MHC class II transcription by interactions with components of the basal transcription machinery such as TAF II 32 Fontes et al., 1997) . Several lines of evidence demonstrate that MHC class II expression is dependent on the expression of CIITA. CIITA is not only required for constitutive expression of the MHC class II genes, but is also a required mediator of IFN-g induced expression of the MHC class II genes (Steimle et al., 1993 (Steimle et al., , 1994 Chang et al., 1994 Chang et al., , 1996 Chin et al., 1994) . MHC class II expression is quantitatively correlated with CIITA expression , and the introduction of exogenous CIITA in normal cells can drive the expression of the MHC class II genes (Steimle et al., 1994; Chang et al., 1994; Chin et al., 1994; Bradley et al., 1997) .
The CIITA expression pattern parallels that of the MHC class II genes in that CIITA is constitutively expressed in MHC class II-positive cells and is induced by IFN-g in MHC class II-negative IFN-g-inducible cells (Steimle et al., 1993 (Steimle et al., , 1994 Chang et al., 1994) . The tissuespeci®c expression of CIITA is regulated by alternative use of four dierent promoters of the CIITA gene (Muhlethaler-Mottet et al., 1997) . Tissue-speci®c activation of the promoters results in CIITA transcripts with dierent ®rst exons, each spliced to the common second exon. In dendritic cells and B cells, in which CIITA as well as the MHC class II genes are constitutively expressed, CIITA gene expression is driven by type I and type III promoters, respectively. The function of the CIITA type II promoter is not well understood. IFN-g induced transcription of CIITA in many other cell types, such as ®broblasts, endothelial cells, and macrophages, is directed by the CIITA type IV promoter.
Multiple putative DNA elements, including an NFGMa site, a GAS element, an E box, and an interferon regulatory factor element (IRF-E), have been identi®ed in the proximal CIITA type IV promoter (MuhlethalerMottet et al., 1997). The GAS element, E box, and IRF-E are essential for the induction of the promoter by IFNg (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1999) . IFN-g induction of the CIITA type IV promoter is mediated by STAT1 and IRF-1, which bind to the GAS site and the IRF-E, respectively (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1999) . STAT1 activates the CIITA type IV promoter by cooperative interaction with USF-1, a ubiquitous transcription factor that binds to the E box adjacent to the GAS element (MuhlethalerMottet et al., 1998) . IRF-1, a member of the IRF family (Nguyen et al., 1997; Harada et al., 1998) , is induced by IFN-g through activation of STAT1 (Fujita et al., 1988) . CIITA mRNA induced by IFN-g is drastically reduced in kidneys derived from IRF-1 knock-out (KO) mice, indicating a critical role for IRF-1 in CIITA induction by IFN-g (Hobart et al., 1997) . The IRF-E of the CIITA type IV promoter is essential for promoter activation by IFN-g (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1999; Nikcevich et al., 1999) . Results from co-transfection experiments revealed that the human CIITA type IV promoter is activated by IRF-2, another member of the IRF family (Xi et al., 1999 , Koenig Merediz et al., 2000 . Also, IRF-2 synergizes with IRF-1 in the activation of the human CIITA type IV promoter (Xi et al., 1999) . DNA binding assays indicate that IRF-1 and IRF-2 can co-occupy the IRF-E of the human CIITA type IV promoter (Xi et al., 1999) .
The putative regulatory elements of the human and mouse CIITA type IV promoters, including the IRF-E sites, are highly conserved (Muhlethaler-Mottet et al., 1997) . In this study, we determined that, like the human CIITA type IV promoter, the mouse CIITA type IV promoter is cooperatively activated by mouse IRF-1 and IRF-2, and that the mouse CIITA IRF-E can be simultaneously occupied by IRF-1 and IRF-2. To determine whether IRF-2 is relevant to the function of the endogenous CIITA promoter, we examined the eect of IRF-2 loss on CIITA expression using IRF-2 defective mice. These studies indicate that IRF-2 is critical for the expression of CIITA in vivo.
Results
Cooperative activation of mouse CIITA type IV promoter by IRF-1 and -2 A mouse genomic DNA fragment encompassing the 7334 and +63 region of the CIITA type IV promoter (Muhlethaler-Mottet et al., 1997) was subcloned into the pGL3 luciferase reporter vector (CIITAPIV/pGL3). In addition to the IRF-E, the promoter reporter construct contains other putative DNA elements, including an NF-GMa site, a GAS box and an E box (Muhlethaler-Mottet et al., 1997) . The promoter reporter construct was co-transfected with mouse IRF-1 and IRF-2 into mouse embryonic ®broblasts (MEFs) from IRF-1 and IRF-2 double knock-out mice. When 0.1 mg of expression vector was co-transfected with the promoter, IRF-1 activated the promoter to a limited extent (3.9-fold). Increasing the amount of IRF-1 expression vector (to 0.2 mg) did not further enhance the promoter activity (Figure 1a ). Compared to IRF-1, IRF-2 activated the promoter to a greater extent (7.7-fold) when 0.1 mg of the expression vector was cotransfected with the promoter (Figure 1a ). When 0.1 mg of each IRF-1 and IRF-2 expression vectors were cotransfected, the promoter was synergistically activated (21.9-fold). This promoter activity could also be achieved by co-transfection with 0.2 mg of IRF-2 alone ( Figure 1a) . Thus, like the human CIITA type IV promoter (Xi et al., 1999) , the mouse promoter is cooperatively activated by IRF-1 and IRF-2, and more responsive to IRF-2 than IRF-1. Sequence analysis of the mouse CIITA type IV promoter revealed one IRF-E site located at 771 of the promoter (Muhlethaler- Co-occupancy of mouse CIITA IRF-E by IRF-1 and IRF-2 IRF-1 and IRF-2 can co-occupy the human CIITA IRF-E, which must account for the cooperative activation of the CIITA type IV promoter by IRF-1 and IRF-2 (Xi et al., 1999) . To determine whether mouse IRF-1 and mouse IRF-2, which are 75% and 87% homologous to their human counterparts, respectively, could co-occupy the mouse CIITA IRF-E, we performed an EMSA using in vitro translated mouse IRF-1 and IRF-2 and the mouse IRF-E as a probe. To facilitate the detection of the DNA protein complex formed by co-occupancy of the IRF-E by IRF-1 and IRF-2, referred to as hetero-occupancy (Xi et al., 1999) , a C-terminal truncated form of IRF-2 containing the N-terminal 224 amino acids of IRF-2, termed IRF-2/T, was employed in the EMSA. A 46 bp DNA fragment that spans the 788 to 743 region (Muhlethaler-Mottet et al., 1997) of the mouse CIITA type IV promoter containing the IRF-E was used as probe. When small amounts of the proteins (IRF-1, IRF-2 or IRF-2/T) were added to the probe, a highmobility complex representing the binding of the IRF-E by one molecule of IRF-1, IRF-2 or IRF-2/T, respectively, was observed ( Figure 2 ). When increasing amounts of the proteins were added, a second, slower migrating complex was apparent. Like the fast migrating complex, the slower migrating complex could not be competed by excess mutant IRF-E ( Compared to the binding of two IRF-1 molecules to the IRF-E, the co-occupancy of the IRF-E by IRF-1 and IRF-2/T is highly ecient. The hetero-occupancy complex was detectable when 1.5 ml of in vitro translated IRF-1 and IRF-2/T was used in the EMSA (Figure 2, lane 11) . However, the co-occupancy of the IRF-E by two IRF-1 molecules was not detectable when 2 ml of IRF-1 were added to the probe (Figure 2 , lane 4).
Reduced IFN-g induction of CIITA in kidneys and lungs of IRF-2 KO mice For both the human and mouse, data indicate that IRF-1 and -2 can co-occupy and co-activate the CIITA type IV promoter. However, it has not been determined for either case whether this cooperativity is: (i) relevant to the expression of the endogenous gene; or (ii) relevant to IFN-g induced CIITA. To address these issues, we examined the expression of CIITA in IRF-2 knock-out mice. IRF-2 KO mice and WT mice were injected with 100 000 IU of mouse IFN-g, and the kidneys and lungs were harvested 4 h later. Total RNA was analysed by RPA for CIITA mRNA. First, we performed RPAs using an antisense RNA probe that protected a 3' end region of CIITA mRNA common to all types of CIITA transcripts driven by four dierent promoters (types I, II, III and IV). Compared to the WT mice, IFN-g induced CIITA mRNA in the kidneys and lungs of IRF-2 KO mice was reduced by 40 ± 60% (Figure 3a) , i.e., about one-half of the amount of CIITA mRNA is dependent on IRF-2. A similar reduction of CIITA mRNA induced by IFN-g in the kidneys of IRF-2 KO mice was also observed in another, separate experiment (data not shown). To learn whether CIITA induction was more impaired in IRF-2 KO mice with lower amounts of exogenous IFN-g, we compared the IFN-g induction of CIITA mRNA in the kidneys and lungs from the IRF-2 KO mouse and the WT mouse injected with 20 000 IU of IFN-g. The reduction of CIITA mRNA induction in both the kidney and lung (50 and 40%, respectively) ( Figure 3b ) from the IRF-2 KO mouse injected with 20 000 IU IFN-g was comparable to that observed in the mice injected with 100 000 IU IFN-g. Thus, like the IRF-1 KO mice (Hobart et al., 1997) , the IRF-2 KO mice have impaired IFN-g induction of CIITA in the kidneys and the lungs.
To determine to what extent the reduction of CIITA induction in IRF-2 KO mice was due to the reduction of the type IV CIITA mRNA induction, we performed an RPA using an RNA probe speci®c for the type IV CIITA mRNA. The probe protected +1 to +59 region of the mouse type IV CIITA mRNA. Compared to WT mice, the type IV CIITA mRNA in the kidneys of IRF-2 KO mice induced by 100 000 IU IFNg was reduced by an average of 65% (Figure 4a) . A greater reduction (*80%) of the type IV CIITA mRNA induction was observed in kidneys and lungs from IRF-2 KO mice injected with 20 000 IU IFN-g ( Figure  4b ). Thus, the reduction of CIITA mRNA induction by IFN-g in IRF-2 KO mice was, at least in part, due to the reduction of the type IV CIITA mRNA induction.
Reduced basal CIITA expression in the kidneys of IRF-2 KO mice Mouse kidneys express a limited amount of basal CIITA mRNA (Hobart et al., 1997) . To assess the eect of loss of IRF-2 expression on the basal CIITA expression, we compared the basal CIITA mRNA levels in the kidneys from the IRF-2 KO mice and WT mice. We performed an RPA to assay for the basal total CIITA mRNA using the non-type-speci®c CIITA probe as described above. Compared to the WT mice, the basal total CIITA mRNA level in the kidneys of IRF-2 KO mice was reduced by approximately 70% (Figure 5 ). To avoid ®lm saturation that would aect accurate quanti®cation, signals obtained from a short exposure of a b-actin RPA gel was used as the internal control. The basal CIITA mRNA levels in the lungs from both IRF-2 KO mice and WT mice were too low for accurate quanti®cation and comparison. As can be determined by inspection of Figure 4 , we were not able to detect any basal level of type IV CIITA mRNA. We cannot rule out the possibility that the probe used to detect the total CIITA mRNA is more ecient at detecting type IV mRNA than is the type IV speci®c probe. Thus, the eect of the lack of IRF-2 on the basal level of CIITA mRNA may be due to a reduced level of basal type IV RNA or a reduced level of mRNA derived from one or more of the other CIITA promoters (See Discussion).
Discussion
The human CIITA type IV promoter is cooperatively activated by human IRF-1 and IRF-2 (Xi et al., 1999) . Human and mouse responses to IFN inducible genes are similar with respect to promoter activation, with some exceptions. For example, although the promoters of the human and mouse guanylate binding protein (GBP) gene both have GAS and IRF-E elements, the GAS element in the mouse promoter, unlike its human counterpart, appears to be dispensable for IFN-g inducibility of the promoter (Lew et al., 1991; Briken , 1995) . In addition, while the human GBP promoter is responsive to both IFN-a and -g (Lew et al., 1991) , the mouse GBP promoter appears to only respond to IFN-g (Briken et al., 1995) . Although the mouse CIITA type IV promoter has an IRF-E sequence identical to its human counterpart (Muhlethaler-Mottet et al., 1997), adjacent sequences are dierent. The roles of the adjacent sequences in IRF hetero-occupancy or in cooperative activation by IRF-1 and -2 are unknown. Also, neither the mouse IRF-1 nor the mouse IRF-2 is identical to the human counterpart. In this study, we determined that the mouse CIITA type IV promoter is cooperatively activated by mouse IRF-1 and IRF-2 (Figure 1) . DNA binding assays demonstrate that the IRF-E of the mouse CIITA promoter, like its human counterpart, can be co-occupied by IRF-1 and IRF-2 ( Figure  2 ). The mechanism of the cooperative binding of the CIITA IRF-E by IRF-1 and IRF-2 is still unknown. However, recent evidence (Fujii et al., 1999) indicates that the cooperative binding of an IRF-E identical to the CIITA IRF-E by two IRF-2 molecules is achieved by sequential binding of IRF-2 to the IRF-E. Binding of the IRF-E by the ®rst IRF-2 molecule leads to the bending of the DNA in a way favoring the binding of the second IRF-2 molecule to the IRF-E. IRF-1 binds to the CIITA IRF-E less eciently than IRF-2 ( Figure  2 ). Thus, it is possible that binding of the CIITA IRF-E by an IRF-2 molecule may facilitate the binding of the IRF-E by an IRF-1 molecule.
To learn whether IRF-2, like IRF-1 (Hobart et al., 1997) , is critical for the IFN-g induction of the endogenous CIITA gene, we examined the CIITA induction by IFN-g in IRF-2 KO mice. CIITA mRNA was induced in the kidneys and lungs of both WT and IRF-2 KO mice. However, we found that CIITA mRNA induced by IFN-g is signi®cantly reduced in both the kidneys and lungs of the IRF-2 KO mice injected with either a high amount (100 000 IU) or a lower amount (20 000 IU) of IFN-g (Figure 3 ). The CIITA type III promoter is also IFN-g inducible in several cell types (Piskurich et al., 1998 . However, unlike the CIITA type IV promoter, the IFN-g induction of the CIITA type III promoter is dependent only on a GAS element (Piskurich et al., 1998 . In addition, the CIITA type III promoter is activated by STAT1 and not by IRF-1 . Thus, the reduction of CIITA observed in the IRF-2 KO mice is most likely due to the reduction of CIITA type IV promoter activity. This conclusion was veri®ed by the analysis of IFN-g induced type IV CIITA mRNA, revealing that the type IV CIITA mRNA induced by IFN-g was markedly reduced in IRF-2 KO mice (Figure 4) .
We observed a 70% reduction of the basal total CIITA mRNA in the kidneys from the IRF-2 KO mice ( Figure 5 ). The 70% reduction of the basal total CIITA mRNA in kidneys of IRF-2 KO mice was apparently due to the reduction of the basal non-type IV CIITA mRNA, because no type IV CIITA mRNA can be detected with the type IV speci®c probe. It is possible that most of the basal non-type IV CIITA mRNA in kidneys was the type III CIITA mRNA, which would be constitutively expressed in B cells potentially residing in the kidneys. IRF-2 KO mice have a de®ciency in B cell development (Matsuyama et al., 1993) , thus explaining the reduction of the basal type III CIITA expression in kidney.
Reduced CIITA induction by IFN-g in IRF-1 KO mice leads to impaired MHC class II expression (Hobart et al., 1997) . Since CIITA expression is also a b Figure 3 IFN-g induction of CIITA in IRF-2 KO mice. IRF-2 KO (7/7) and WT (+/+) mice were i.p. injected with 100 000 IU (a) or 20 000 IU (b) mouse rIFN-g. Total RNA was isolated from kidneys and lungs 4 h later, and was analysed by RPA for total CIITA (non-type-speci®c) and b-actin mRNAs (see Materials and methods). The relative CIITA level was determined by normalizing CIITA mRNA to b-actin mRNA, as quanti®ed by Phosphor Imager analysis. The relative CIITA level of WT mouse was set at unity impaired in IRF-2 KO mice, it is likely that IRF-2 KO mice would have decreased MHC class II expression, especially decreased cell surface expression of MHC class II molecules, the assembly of which requires coordinated expression of a and b chains. If the loss of half the CIITA led to a twofold reduction in the cellular concentration of each MHC class II chain, as well as a twofold reduction in the invariant chain, and if the rate of assembly is limited by the concentrations of the two MHC class II chains and the invariant chain, then IFN-g induction of surface class II in the IRF-2 KO mice could be substantially reduced.
Previous studies revealed that IRF-2 KO mice exhibit increased susceptibility to infection with Venezuelan equine encephalitis virus (Grieder and Vogel, 1999; Schoneboom et al., 2000) and high mortality following lymphocytic choriomeningitis virus infection (Matsuyama et al., 1993) . Although the defect(s) responsible for the de®cient host defense against virus infection in IRF-2 KO mice is unknown, the data reported here suggest a possible explanation: insucient viral antigen presentation by MHC class II. IRF-2, like IRF-1, is implicated in lymphocyte development. IRF-2 KO mice exhibit severe reduction of mature TCRab + T cells as well as mature B cells in the bone marrow (Matsuyama et al., 1993) , all of which is potentially traceable to low levels or lack of MHC class II. Future experiments to determine the impact of the loss of IRF-2 on MHC class II expression in speci®c cellular compartments, such as in macrophages, dendritic cells, or thymus epithelium, will allow a test of the hypothesis that IRF-2 KO mice do not resist viral infection because of the impact of IRF-2 loss on CIITA expression.
Materials and methods

Cell lines and cultures
The mouse embryonic ®broblasts (MEFs), derived from an IRF-1 and -2 double knockout mouse (IRF-1/2 7/7 ) (Vaughan et al., 1995) (generously provided by G Stein, University of Massachusetts Medical Center), and the mouse ®broblast cell line NIH3T3 were cultured in DMEM with 10% FBS, penicillin/streptomycin and L-glutamine.
WT and IRF-2 KO mice
The homozygous IRF-2 knock-out (KO) mice and wild-type (WT) mice were generated by breeding of heterozygous IRF-2 KO mice (C57BL/6) (generously provided by T Mak, Amgen Institute, Ontario, Canada). All the homozygous IRF-2 KO mice and WT mice were con®rmed by PCR of mouse genomic DNA according to the instructions of the provider. The mice were maintained in a pathogen-free environment at the College of Medicine Animal Facility at the University of South Florida.
IFN-g injections and RNA isolation
Ten-to twelve-week-old IRF-2 KO mice and WT mice were injected i.p. with the mouse recombinant IFN-g (rIFN-g) (R&D Systems) and were sacri®ced at 4 h. Kidneys and lungs were harvested and homogenized in TRIZOL 1 Reagent (Life Technologies) with a polytron. Total RNA was then isolated Figure 4 IFN-g induction of the type IV CIITA mRNA in IRF-2 KO mice. IRF-2 KO (7/7) and WT (+/+) mice were i.p. injected with 100 000 IU (a) or 20 000 IU (b) mouse rIFN-g. Four hours later, the total RNA was isolated from the kidneys and the lungs. The IFN-g induction of type IV CIITA mRNA in the kidneys and lungs was analysed by RPA using a probe speci®c for the type IV CIITA mRNA (see Materials and methods). The relative CIITA type IV mRNA level was determined by normalizing the type IV CIITA mRNA to b-actin mRNA, as quanti®ed by Phosphor Imager analysis. The data in a represent two independent mice for both the WT and KO mice. In a and b, the relative type IV CIITA mRNA level of one WT mouse was set at unity from the homogenized tissue samples according to manufacturer's recommendations.
Mouse CIITA type IV promoter reporter constructs and the IRF-1 and -2 expression vectors For construction of the mouse CIITA type IV promoter luciferase construct, CIITAPIV/pGL3, a DNA fragment corresponding to positions 7334 to +63 of the mouse CIITA type IV promoter (Muhlethaler-Mottet et al., 1997) was generated by PCR ampli®cation of mouse kidney genomic DNA (Clontech) using primers as follows: 5'-CCCGAGCTCGGTGTAGATGAGGTGGCTT, 5'-CCGA-AGCTTGCTTCTGAGTGCTGCCTG. The PCR product was digested with SacI and HindIII and subcloned into the pGL3 luciferase vector (Promega). The mouse CIITA type IV promoter with the mutant IRF-E, mutCIITAPIV/pGL3, was generated by PCR-based mutagenesis. First, the wild-type promoter was subcloned into HindIII and EcoRI sites of PUC13 to generate CIITAPIV/PUC13. A DNA fragment was then generated by PCR using CIITAPIV/pGL3 as the template and the following primers: 5'-CTGAAGGTGTA-GACAGAACTTAGAAGGGGGAAAAGCGCCACAGAT-AC (the mutated nucleotides in the IRF-E are underlined), 5'-CCGAAGCTTGCTTCTGAGTGCTGCCTG. The PCR product was digested with AccI and HindIII and subcloned into CIITAPIV/PUC13 to replace the wild-type IRF-E. The resulting plasmid, mutCIITAPIV/PUC13 was digested with HindIII and EcoRI to generate a fragment containing the mutant IRF-E, which was then subcloned into HindIII and EcoRI sites of CIITAPIV/pGL3 to replace the corresponding fragment containing the wild-type IRF-E. Both the wild-type and mutant promoter reporter constructs were veri®ed by DNA sequencing.
For construction of mouse IRF-1 and -2 expression vectors, IRF-1/pcDNA3 and IRF-2/pcDNA3, the full-length IRF-1 and -2 cDNAs derived from CMVBL/IRF-1 and CMVBL/IRF-2 (generously provided by J Hiscott, Lady Davis Institute for Medical Research, Quebec, Canada), respectively, were subcloned into pcDNA3 (Invitrogen).
Transient transfection
For transient transfection of IRF-1/2 7/7 MEFs and NIH3T3 cells, a total of 10 5 cells per well in 24-well plates were cotransfected with the CIITA type IV promoter luciferase reporter constructs and IRF-1/pcDNA3 and/or IRF-2/ pcDNA3 by LipofectAMINE PLUS TM reagent (Life Technologies) according to manufacturer's recommendations. Cells were harvested 24 h after transfection and lysed with 100 ml of passive lysis buer (Promega). A total of 20 ml of cell lysate were analysed for luciferase activity in 100 ml of luciferase substrate (Promega) by a luminometer (Turner Designs).
RNase Protection Assay (RPA)
A 32 P-labeled antisense CIITA probe, which covers positions 2724 to 3152 of mouse CIITA RNA, common to all four types of CIITA mRNAs, was synthesized by in vitro transcription of PvuI digested plasmid mCIITA-2 (O'Keefe et al., 1999) (generously provided by E Benveniste, University of Alabama, Birmingham) using T7 RNA polymerase (Promega). The 32 P-labeled b-actin antisense RNA probe was prepared by in vitro transcription of pTRI-actin-mouse template (Ambion) using T7 RNA polymerase in the presence of 50-fold unlabeled UTP. Twenty-®ve mg of total RNA isolated from kidneys and lungs was analysed by RPA as previously described (Blanck et al., 1990; Lu et al., 1996) . For synthesis of the RPA probe speci®c for the mouse type IV CIITA mRNA, the RPA templates were generated by PCR using the following primer set: 5'-CGCGGAATTCAT AGCTGCCAGGAGAC (forward primer, an EcoRI site is indicated as the italic type); 5'-TAATACGACTCACTA-TAGGGAGGAAGCTTGCTCTGAGTG (reverse primer, the T7 promoter is underlined). The plasmid CIITAPIV/ pGL3 containing 7334 to +63 region of the mouse CIITA type IV gene was used as the PCR template. The PCR generated a DNA fragment containing 725 to +59 region of the CIITA type IV gene. The PCR product was digested with EcoRI and gel puri®ed. The PCR product (100 ng) was used for in vitro synthesis of the RPA probe by T7 RNA polymerase as described previously (Blanck et al., 1990; Lu et al., 1996) . The synthesized 32 P-labeled probe protected +1 to +59 region of the mouse CIITA type IV mRNA. The RPA for the mouse type IV CIITA mRNA was performed as described above except that the mouse type IV CIITA mRNA RPA probe was used as the probe and that the hybridization was performed at 378C instead of 458C. The samples were electrophoresed on an 8 M urea, 12% polyacrylamide gel in 16TBE. CIITA and actin mRNAs were quanti®ed by Phosphor Imager analysis.
In vitro transcription and translation
For full-length IRF-1 and -2, IRF-1/pcDNA3 and IRF-2/ pcDNA3 (200 ng), linearized by XbaI and TthI, respectively, Figure 5 Basal CIITA expression in IRF-2 KO mice. Total RNA isolated from kidneys of IRF-2 KO (7/7) and WT (+/+) mice was analysed for the basal total CIITA mRNA by RPA using the non-type-speci®c CIITA RPA probe. Quanti®cation was performed as described in Figure 3 . For accurate quanti®cation, a short exposure of the b-actin RPA gel was used to avoid ®lm saturation were in vitro transcribed by T7 RNA polymerase (Promega) and translated by nuclease-treated rabbit reticulocyte lysate (Promega), as previously described (Xi et al., 1999) . The Cterminal truncated IRF-2 (IRF-2/T), which contains the Nterminal 224 amino acids of IRF-2, was generated by in vitro transcription and translation of BbsI linearized IRF-2/ pcDNA3.
Electrophoretic mobility shift assay (EMSA)
A 46 bp DNA fragment that spans the 788 to 743 region of the mouse CIITA type IV promoter (Muhlethaler-Mottet et al., 1997) containing either the wild-type or the mutant IRF-E was generated by annealing two complementary oligonucleotides (Integrated DNA Technologies) as previously described (Xi et al., 1999) . The sequences of the oligonucleotides are as follows (the IRF-E is underlined): wild-type, 5'-AGCTGAAGGTGTAGACAGAAAGTGAA-AGGGGGAAAAGCGCCA (sense strand), 5'-TCTGT-GGCGCTTTTCCCCCTTTCACTTTCTGTCTACACCTTC (antisense strand); mutant 5'-AGCTGAAGGTGTAGACAGAActTagAAGGGGGAAAAGCGCC A (sense strand), 5'-TCTGTGGCGCTTTTCCCCCTTctAagTTCTGTCTACAC-CTTC (antisense strand). The mutated nucleotides are indicated by lowercase type. The 32 P-labeled wild-type IRF-E probe was generated by the Klenow ®ll-in reaction of the annealed wild-type fragment, as previously described (Xi et al., 1999) .
EMSA was performed as previously described (Xi et al., 1999) except that 8006instead of 806molar excess unlabeled wild-type or mutant IRF-E competitor was used in the competition experiments.
